Physician profile
Robert I Picker
NPI 1275574691
$9,023.84
in general payments reported to CMS, 2019-2025
24 companies · $1,000 in 2025
The $1,000 reported for 2025 was more than what 81% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $692 · 2020: $49.99 · 2021: $199 · 2022: $1,938 · 2023: $2,408 · 2024: $2,737 · 2025: $1,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,118 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,117.96 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,568.50 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,115.39 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $970.84 | 2022-2025 | Lybalvi, Aristada |
| Abbvie INC. | $826.87 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $719.28 | 2019-2024 | Invega Sustenna, Spravato, Invega Trinza |
| Neurocrine Biosciences, INC. | $596.92 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $480.23 | 2021-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $422.11 | 2022-2024 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $396.61 | 2022-2025 | Austedo, Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $338.46 | 2024-2025 | Cobenfy |
| Indivior INC. | $259.32 | 2019-2025 | Sublocade, Perseris |
| Almatica Pharma LLC | $257.73 | 2023-2025 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $232.02 | 2022-2025 | Trintellix |
| Axsome Therapeutics, INC. | $184.99 | 2022-2025 | Auvelity, Sunosi |
| Bausch Health US, LLC | $168.82 | 2022-2023 | Aplenzin |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $120.71 | 2019 | |
| Avanir Pharmaceuticals, INC. | $74.42 | 2022 | |
| Neuronetics, INC. | $66.74 | 2022 | |
| Biogen, INC. | $58.85 | 2025 | Zurzuvae |
| Tris Pharma INC | $58.06 | 2023-2024 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $41.43 | 2022-2023 | Belsomra |
| Ironshore Pharmaceuticals INC. | $23.76 | 2022 | |
| Corium, LLC | $23.06 | 2022 | |
| Adlon Therapeutics L.P. | $18.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Picker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.